Original articleHalf-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy: One-Year Results of a Randomized Controlled Trial
Section snippets
Study Design and Patient Recruitment
This study was a prospective, double-masked, randomized placebo-controlled trial conducted in the Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong. Patients with acute symptomatic CSC of 3 months' duration or less were recruited from Hong Kong Eye Hospital and Prince of Wales Hospital from December 2004 through December 2005. Inclusion criteria included: (1) patients with best-corrected visual acuity (BCVA) of 20/200 or better; (2) presence of subretinal
Results
Sixty-three eyes in 63 patients with acute CSC were recruited, of which 42 eyes were randomized to safety-modified PDT with half-dose verteporfin and 21 eyes were randomized to placebo. Figure 1 shows the flow of the patients in the study. At 12 months, 5 patients (3 in the verteporfin group and 2 in the placebo group) were lost to follow-up, and the remaining 58 (92.1%) patients were included in the analysis. The mean age±standard deviation (SD) of the patients was 41.0±6.7 years (range, 25–58
Discussion
Although CSC generally is considered as a self-limiting and benign condition, some patients may experience significant visual impairment caused by recurrent attacks of CSC, persistent chronic neurosensory retinal detachment, or RPE atrophy.5, 6 Moreover, because many patients are of working age, visual symptoms may interfere with their activities considerably. The ideal treatment option for CSC would be one that can result in visual improvement, can shorten the duration of symptoms, and can
References (39)
- et al.
Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography
Ophthalmology
(1989) - et al.
Choroidal capillary and venous congestion in central serous chorioretinopathy
Am J Ophthalmol
(1996) - et al.
Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up
Ophthalmology
(1997) Argon laser photocoagulation treatment in central serous chorioretinopathy
Ophthalmology
(1986)- et al.
Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy
Am J Ophthalmol
(1983) - et al.
The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002
Ophthalmology
(2008) - et al.
Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy
Am J Ophthalmol
(2003) - et al.
Chronic central serous chorioretinopathy: photodynamic therapy
Am J Ophthalmol
(2004) - et al.
Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy
Ophthalmology
(2005) - et al.
Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy
Am J Ophthalmol
(2004)
Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy
Ophthalmology
Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization
Am J Ophthalmol
Acetazolamide for central serous retinopathy
Ophthalmology
Photodynamic therapy for focal RPE leaks
Ophthalmology
Photodynamic therapy for central serous chorioretinopathy using a reduced dose of verteporfin
Can J Ophthalmol
Pathogenesis of disciform detachment of neuroepithelium
Am J Ophthalmol
Type-A behavior and central serous chorioretinopathy
Retina
Visual function abnormalities in central serous retinopathy
Arch Ophthalmol
Cited by (0)
Manuscript no. 2008-150.
Financial Disclosure(s): Dr Lai has served as a consultant to an advisory board of Novartis, Inc. All other authors have no financial interest to declare.